Form 4: Madrigal Pharmaceuticals Executive Sells Shares to Cover Tax Obligations

Rebecca Taub, a Madrigal Pharmaceuticals executive, sold 1,689 shares of common stock to cover tax obligations related to vesting restricted stock units.

Summary

• Rebecca Taub, President of R&D and CMO at Madrigal Pharmaceuticals, sold 1,689 shares of common stock on January 17, 2025, at a price of $273.41 per share.
• The sale was executed by the issuer to cover tax withholding obligations associated with the vesting of restricted stock units.
• This transaction was automatic and not at the discretion of Ms. Taub.
• Following the transaction, Ms. Taub directly owns 457,310 shares of common stock.
• She also indirectly owns 655,540 shares through SQN LLC, where she and her spouse are managing members.

Sentiment

Score: 5

Explanation: The document reflects a routine transaction related to executive compensation and does not indicate any positive or negative sentiment about the company's performance or future prospects.

Management Comments

• The sale reported on this Form 4 represents the number of shares sold by the Issuer on behalf of the Reporting Person to cover tax withholding obligations in connection with the vesting of restricted stock units.
• This sale was automatic and not at the discretion of the Reporting Person.
• The Reporting Person disclaims beneficial ownership of these securities except to the extent of her pecuniary interest therein, if any, and the inclusion of these shares in this report shall not be deemed an admission of the beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose.

Industry Context

This is a routine transaction for executives who receive stock-based compensation. It is common for companies to sell shares on behalf of executives to cover tax obligations when restricted stock units vest.

Comparison to Industry Standards

• Similar transactions are common among executives at publicly traded companies, particularly in the biotechnology and pharmaceutical sectors.
• Companies like Regeneron, Gilead, and Vertex often see similar Form 4 filings from their executives related to stock sales for tax purposes.
• These transactions are generally viewed as a normal part of executive compensation and do not typically indicate a change in the executive's outlook on the company's prospects.

Stakeholder Impact

• The transaction has a minimal impact on shareholders as it is a routine sale to cover tax obligations.
• The sale does not affect the company's operations or financial position.

Key Dates

Keywords

Madrigal Pharmaceuticals, stock sale, insider trading, Form 4, executive, tax obligations, restricted stock units